19 assets in Malignant Colon Neoplasm

Therapeutic assets addressing Malignant Colon Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fluorouracilum Malignant Colon Neoplasm	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P2	BB (65)
Tranexamic Acid Malignant Colon Neoplasm	Assaf-Harofeh Medical Center	P4	BB (65)
Cetuximab Malignant Colon Neoplasm	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P2	B (60)
Irinotecan Malignant Colon Neoplasm	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P2	B (60)
Oxaliplatin Malignant Colon Neoplasm	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	B (60)
Nivolumab Malignant Colon Neoplasm	M.D. Anderson Cancer Center	P1/2	B (57)
Capecitabine Malignant Colon Neoplasm	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	CCC (53)
Clostridium Butyricum Malignant Colon Neoplasm	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	CCC (53)
Encorafenib Malignant Colon Neoplasm	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P2	CCC (53)
Mesalamine Malignant Colon Neoplasm	Ann-Sofie Backman	P2	CCC (53)
Nbt-Nm108 Malignant Colon Neoplasm	Howard S. Hochster, MD	P2	CCC (53)
Niraparib Malignant Colon Neoplasm	Tempus AI	P2	CCC (53)
Zanidatamab Malignant Colon Neoplasm	Emory University	P2	CCC (53)
Abemaciclib Malignant Colon Neoplasm	M.D. Anderson Cancer Center	P1/2	CCC (48)
SX682 Malignant Colon Neoplasm	M.D. Anderson Cancer Center	P1/2	CCC (48)
Temuterkib Malignant Colon Neoplasm	M.D. Anderson Cancer Center	P1/2	CCC (48)
Hbi-2376 Malignant Colon Neoplasm	HUYABIO International, LLC.	P1	CC (43)
Propofol Malignant Colon Neoplasm	Seoul National University Hospital	N/A	D (30)
Sevoflurane Malignant Colon Neoplasm	Seoul National University Hospital	N/A	D (30)